ACM
NRIX icon

Accent Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Accent Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Buy
748
+180
+32% +$3.07K 0.01% 161
2026
Q1 		$8.8K Buy
568
+188
+49% +$3.12K ﹤0.01% 212
2025
Q4 		$7.21K Buy
380
+310
+443% +$4.45K ﹤0.01% 243
2025
Q3 		$647 Sell
70
-180
-72% -$1.87K ﹤0.01% 371
2025
Q2 		$2.85K Buy
+250
New +$2.7K ﹤0.01% 372

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Accent Capital Management's NRIX Position: Q2 2026 in Review

Accent Capital Management increased its Nurix Therapeutics (NRIX) stake by 32% in Q2 2026, buying an estimated $3.07K and bringing the position to 748 shares worth $18.1K. The position accounts for 0.01% of the portfolio, ranked #161.

Accent Capital Management first reported a position in NRIX in Q2 2025 and has held it in 5 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Accent Capital Management held 748 shares of Nurix Therapeutics worth $18.1K as of Q2 2026.
  • Accent Capital Management bought 180 Nurix Therapeutics shares in Q2 2026, an estimated $3.07K.
  • Nurix Therapeutics made up 0.01% of Accent Capital Management's portfolio in Q2 2026, its #161 holding.
  • Accent Capital Management first reported a position in Nurix Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.